Our study indicates that a FAK inhibitor could be useful for treating mesothelioma, and that molecular testing of E-cadherin mRNA levels may be a useful indicator of PND-1186 sensitivity in MPM patients (Figure 2). This evidence concerns the gene PTK2 and mesothelioma.